SCHEMBL5642014

SCHEMBL5642014

Cc1n[nH]c(Sc2cc(Cl)cc(Cl)c2)c1C(c1ccccn1)C(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.37
PDE10A Q9Y233 1/20 0.37
KCNA5 P22460 1/20 0.32
SLC6A4 P31645 3/20 0.31
CHRM2 P08172 2/20 0.31
CHRM5 P08912 2/20 0.31
CHRM1 P11229 2/20 0.31
ADRA2B P18089 2/20 0.31
SLC6A2 P23975 2/20 0.31
HRH2 P25021 2/20 0.31
HTR2A P28223 2/20 0.31
HRH1 P35367 2/20 0.31
SLC6A3 Q01959 2/20 0.31
KCNH2 Q12809 2/20 0.31
HRH3 Q9Y5N1 2/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31
NFKB1 P19838 1/20 0.31
THPO P40225 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5643380 0.91 KDM4E (0.38) CYP3A4PDE10ASLC6A4SLC6A2SLC6A3
SCHEMBL5642866 0.89 KDM4E (0.32) CYP3A4PDE10AMAPTKDM4EMEN1
SCHEMBL5641593 0.84
SCHEMBL5640385 0.79 CYP3A4 (0.38) CYP3A4PDE10AKCNA5SLC6A4SLC6A2
SCHEMBL5641732 0.77
SCHEMBL5643063 0.75 CYP3A4 (0.31) CYP3A4SLC6A4SLC6A2SLC6A3CYP2D6
SCHEMBL5642073 0.75 BRD4 (0.31) GAA
SCHEMBL5643540 0.75 MAOA (0.33)
SCHEMBL7165560 0.74 KDM4E (0.31) MAPTKDM4EMEN1USP2ALDH1A1
SCHEMBL6967039 0.72 KCNA5 (0.32) CYP3A4PDE10AKCNA5SLC6A4CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183296-B2 Anti-HIV pyrazole derivatives ROCHE PALO ALTO LLC (US) 2007-02-27 US claimed
US-20040192752-A1 Anti-HIV pyrazole derivatives DYMOCK BRIAN WILLIAM (GB) 2004-09-30 US claimed
EP-1326843-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. Hoffmann-La Roche AG (CH) 2003-07-16 EP claimed
WO-2002030907-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2002-04-18 WO claimed
US-7183296-B2 Anti-HIV pyrazole derivatives ROCHE PALO ALTO LLC (US) 2007-02-27 US disclosed
US-6699887-B2 ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A PYRRAZOLE SULFIDE OR ETHER COMPOUND TO TREAT THE HUMAN IMMUNODEFICIENCY VIRUS INFECTION HOFFMANN-LA ROCHE INC. 2004-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192752-A1 Anti-HIV pyrazole derivatives CYP51A1, TYMP, POLRMT CYP3A4 7/4885PDE10A 2171/4885KCNA5 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.